These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-004286-15 A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride (BCX-1777) Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride (... 2007-03-27 due-trials
Exempt, with results 2005-000627-42 A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydroch... 2007-03-27 not-yet-due
Reported results 2006-005196-17 A phase II, Multicenter, Randomised, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza 2007-07-19 due-trials
Reported results 2007-002093-60 Ensayo de agente único en fase II sobre la forodesina (BCX1777) en el tratamiento del linfoma cutáneo de células T 2011-12-07 due-trials
Not reported 2007-002527-32 A Phase II/III, Multicenter, Ramdomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza 2008-01-23 due-trials
Not reported Terminated 2007-004660-47 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Virologic Activity, Safety, and Pharmacodynamics of Intravenous Peramivir for the Treatment of Experimental Influenza 2008-08-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-012367-34 A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of C... 2012-11-16 bad-data
Reported results 2013-002319-82 A Phase 2a double-blind placebo-controlled 2-period crossover study to evaluate the safety and efficacy of BCX4161 as a prophylactic treatment to reduce the frequency of attacks in subjects with hered... 2014-05-13 due-trials
Reported results 2014-002655-26 OPuS-2 A multicentre, randomised, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX4161 for 12 weeks as an oral prophylaxis treatment... 2016-01-08 due-trials
Reported results 2015-003242-22 OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema 2016-02-26 due-trials
Reported results Terminated 2015-003923-74 A randomized, double-blind, 4 week, placebo-controlled, dose-ranging, parallel-group study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BCX7353 as a preven... 2016-03-29 due-trials
Reported results 2016-001272-29 A randomized, double-blind, placebo-controlled, dose-ranging, parallel-group study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of BCX7353 as a preventative tr... 2017-08-08 due-trials
Reported results 2016-001424-55 A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditar... 2019-01-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003281-27 An Open-Label study to Evaluate the Long-Term Safety of Daily Oral BCX7353 in subjects with Type I and II Hereditary Angioedema 2022-04-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-003966-29 A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in su... 2022-04-06 bad-data
Listed as ongoing, but also has a completion date 2020-000501-93 A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) Uno studio di fase 2, in aperto, per valutare la sicurezza a... 2023-10-04 bad-data
Other 2020-004230-37 An open-label study to provide berotralstat access to subjects with type 1 and 2 hereditary angioedema who were previously enrolled in berotralstat studies not-yet-due
Completed, report not yet due 2020-004403-14 A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturn... 2023-09-18 not-yet-due
Completed, report not yet due 2020-004438-39 A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in S... 2023-09-14 not-yet-due
Reported results 2020-005855-19 An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy 2022-09-23 due-trials
Trial is outside EEC, and reported results 2021-001018-13 A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Unco... bad-data
Ongoing 2021-005932-50 A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE not-yet-due
Ongoing 2021-006776-17 An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst sponsored Study not-yet-due